During pregnancy, the presence of hypertension and proteinuria signal that the patient has preeclampsia (Rogers & Worley, 2016). When seizures develop in this patient, eclampsia is diagnosed. Edema is no longer a required element. Onset can occur any time after 20 weeks of gestation and up to 6 weeks postpartum. Delivery of the fetus and placenta cures this unique disease. Approximately 7% of pregnant women in the United States will develop preeclampsia-eclampsia. Women at risk are primiparas, those with multiple gestation, those with chronic hypertension, diabetes, renal disease, collagen-vascular and autoimmune disorders, and gestational trophoblastic disease. Of the women who develop preeclampsia, 5% will progress to eclampsia. Maternal death can result from uncontrolled eclampsia. Patients with mild preeclampsia may have minimal complaints; in severe cases, the patient may have dizziness and headache with hypertension. A form of severe preeclampsia is identified as HELLP syndrome. The syndrome includes hemolysis, elevated liver enzymes, and low platelets. If the patient progresses to eclampsia, seizures occur. Treatment includes early recognition of subtle changes in blood pressure and weight during prenatal visits. Bed rest is recommended for mild preeclampsia. When the patient convulses, the treatment of choice is 4 to 6 grams of magnesium sulfate, followed by 2 to 3 grams/hr maintenance. Upon stabilization of the mother, delivery needs to proceed to treat the disease and ensure safety of the fetus and the mother. After delivery, magnesium sulfate infusions are continued for at least 24 hours. Resolution of the preeclampsia-eclampsia is indicated by urinary output of over 100 to 200 mL/h and the magnesium sulfate is discontinued.